EVQLV leverages advances in computation to revolutionize the design and development of antibody-based therapeutics, diagnostics, and reagents. EVQLV provides AI-powered de novo antibody discovery and antibody engineering to large molecule discovery scientists at biotechs, pharmaceutical companies, reagent distributors, and universities. EVQLV strives every day to ensure that antibodies (including VHHs, ADCs, and BsAbs) can be developed faster, cheaper, and against hard targets.